StockCIK 1826457
Monte Rosa Therapeutics, Inc. (GLUE): Insider Trades and Fund Holdings
In the past 12 months, Monte Rosa Therapeutics, Inc. insiders reported 0 open-market purchases worth $0 and 1 sale worth $137; 0 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$137Sold by insiders, 12 months
2Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 6, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 6 | Matthew BowenPrincipal Accounting Officer | ▼ SELL | $137 |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Matthew Bowen | Principal Accounting Officer | 0 | $0 | 1 | $137 |
Tracked funds that report GLUE
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 102,500 | $2.48M | ▼ −73.0% |
| Duquesne Family Office | 297,600 | $7K | ▲ New |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →